These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 3660204)
1. Immunohistochemical, electron microscopic, and morphometric studies of human prolactinomas after short-term bromocriptine treatment. Niwa J; Minase T; Mori M; Hashi K Surg Neurol; 1987 Nov; 28(5):339-44. PubMed ID: 3660204 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment. Niwa J; Minase T; Hashi K; Mori M Virchows Arch B Cell Pathol Incl Mol Pathol; 1987; 53(2):89-96. PubMed ID: 2887062 [TBL] [Abstract][Full Text] [Related]
3. Storage and release of secretory granules in human prolactinomas: modification by bromocriptine. Landolt AM; Osterwalder V; Landolt TA J Endocrinol; 1987 Jun; 113(3):495-9. PubMed ID: 3625099 [TBL] [Abstract][Full Text] [Related]
4. Ultrastructural localization of prolactin in the human pituitary prolactinomas and its changes by bromocriptine treatment. Osamura RY; Teramoto A; Watanabe K Acta Pathol Jpn; 1986 Aug; 36(8):1123-30. PubMed ID: 3776529 [TBL] [Abstract][Full Text] [Related]
5. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine. Osamura RY; Watanabe K Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530 [TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: ultrastructural alterations of secretory granules. Saitoh Y; Koizumi K; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H Anticancer Res; 1986; 6(5):1149-55. PubMed ID: 3800323 [TBL] [Abstract][Full Text] [Related]
7. Cytosuppressive effect of bromocriptine on human prolactinomas: stereological analysis of ultrastructural alterations with special reference to secretory granules. Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H Cancer Res; 1986 Mar; 46(3):1507-12. PubMed ID: 3943108 [TBL] [Abstract][Full Text] [Related]
8. [Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: special reference to changes in secretory granules by stereological analysis]. Saitoh Y; Koizumi K; Arita N; Hayakawa T; Aono T; Matsumoto K; Mogami H; Mori H No To Shinkei; 1987 Apr; 39(4):347-54. PubMed ID: 3593602 [TBL] [Abstract][Full Text] [Related]
9. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis. Mori H; Mori S; Saitoh Y; Arita N; Aono T; Uozumi T; Mogami H; Matsumoto K Cancer; 1985 Jul; 56(2):230-8. PubMed ID: 4005795 [TBL] [Abstract][Full Text] [Related]
10. [Pathological changes of prolactinomas treated with bromocriptine]. Teramoto A; Takakura K; Fukushima T; Osamura Y No Shinkei Geka; 1982 Jun; 10(6):619-27. PubMed ID: 7121729 [TBL] [Abstract][Full Text] [Related]
11. Spontaneous sparsely-granulated prolactin-producing pituitary adenomas in aging rats. A prospective study of the effect of bromocriptine. McComb DJ; Hellmann P; Kovacs K; Scott D; Evans WS; Burdman JA; Thorner MO Neuroendocrinology; 1985 Sep; 41(3):201-11. PubMed ID: 4047338 [TBL] [Abstract][Full Text] [Related]
12. Prolactin and growth hormone-producing pituitary adenomas. An immunohistochemical and ultrastructural study. Lloyd RV; Gikas PW; Chandler WF Am J Surg Pathol; 1983 Apr; 7(3):251-60. PubMed ID: 6340535 [TBL] [Abstract][Full Text] [Related]
13. In-vitro effects of bromocriptine on isolated pituitary adenoma cells. Ultrastructural and morphometrical studies. Saeger W; Thiel M; Caselitz J; Lüdecke DK Pathol Res Pract; 1985 Dec; 180(6):697-704. PubMed ID: 3832005 [TBL] [Abstract][Full Text] [Related]
14. Changes in prolactinomas and somatotropinomas in humans treated with bromocriptine. Mori H; Maeda T; Saitoh Y; Onishi T Pathol Res Pract; 1988 Sep; 183(5):580-3. PubMed ID: 3237547 [TBL] [Abstract][Full Text] [Related]
15. Decreased prolactin level in secretory granules and their increased exocytosis in estrogen-induced pituitary hyperplasia in rats treated with a dopamine agonist. Maeda T; Sawada K; Itoh Y; Moriwaki K; Mori H Lab Invest; 1991 Dec; 65(6):679-87. PubMed ID: 1753713 [TBL] [Abstract][Full Text] [Related]
16. Ultrastructural morphology of nontumorous prolactin cells in human pituitaries harboring prolactin-producing adenoma. Jalalah S; Kovacs K; Horvath E J Submicrosc Cytol Pathol; 1988 Apr; 20(2):277-85. PubMed ID: 3395967 [TBL] [Abstract][Full Text] [Related]
17. Ultrastructural morphometry of sparsely granulated prolactin cell adenomas of the human pituitary. McComb DJ; Kovacs K Acta Endocrinol (Copenh); 1978 Nov; 89(3):521-9. PubMed ID: 707008 [TBL] [Abstract][Full Text] [Related]
18. Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells. Landolt AM; Osterwalder V; Landolt TA Experientia; 1985 May; 41(5):640-2. PubMed ID: 3996537 [TBL] [Abstract][Full Text] [Related]
19. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. Bassetti M; Spada A; Pezzo G; Giannattasio G J Clin Endocrinol Metab; 1984 Feb; 58(2):268-73. PubMed ID: 6693536 [TBL] [Abstract][Full Text] [Related]